[go: up one dir, main page]

AR033059A1 - Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada. - Google Patents

Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada.

Info

Publication number
AR033059A1
AR033059A1 ARP020101020A ARP020101020A AR033059A1 AR 033059 A1 AR033059 A1 AR 033059A1 AR P020101020 A ARP020101020 A AR P020101020A AR P020101020 A ARP020101020 A AR P020101020A AR 033059 A1 AR033059 A1 AR 033059A1
Authority
AR
Argentina
Prior art keywords
zinc
insulin
poor
exempt
improved stability
Prior art date
Application number
ARP020101020A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR033059A1 publication Critical patent/AR033059A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulacion farmacéutica que contiene un polipéptido elegido de un grupo que contiene insulina, un metabolito de insulina, un análogo de insulina, un derivado de insulina o combinaciones de los mismos; un tensioactivo o combinacion de varios tensioactivos; opcionalmente, un agente conservante o combinaciones de varios agentes conservantes; y, opcionalmente, un agente isotonico, tampon u otros coadyuvantes o combinaciones de los mismos, estando la formulacion farmacéutica de zinc o siendo pobre en zinc; y a la produccion de preparados de insulina de este tipo.
ARP020101020A 2001-03-23 2002-03-21 Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada. AR033059A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10114178A DE10114178A1 (de) 2001-03-23 2001-03-23 Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität

Publications (1)

Publication Number Publication Date
AR033059A1 true AR033059A1 (es) 2003-12-03

Family

ID=7678654

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020101020A AR033059A1 (es) 2001-03-23 2002-03-21 Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada.
ARP140102020A AR096376A2 (es) 2001-03-23 2014-05-21 Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140102020A AR096376A2 (es) 2001-03-23 2014-05-21 Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada

Country Status (31)

Country Link
US (5) US6960561B2 (es)
EP (2) EP1381385B1 (es)
JP (1) JP4231292B2 (es)
KR (2) KR100987311B1 (es)
CN (1) CN1273187C (es)
AR (2) AR033059A1 (es)
AT (1) ATE497777T1 (es)
AU (1) AU2002302409B2 (es)
BR (1) BRPI0208210B8 (es)
CA (1) CA2441260C (es)
CY (2) CY1111413T1 (es)
DE (2) DE10114178A1 (es)
DK (2) DK1381385T3 (es)
ES (2) ES2393180T3 (es)
HR (1) HRP20030765B1 (es)
HU (1) HU228847B1 (es)
IL (2) IL158057A0 (es)
ME (1) ME00408B (es)
MX (1) MXPA03007942A (es)
MY (1) MY129417A (es)
NO (1) NO326780B1 (es)
NZ (1) NZ528335A (es)
PE (1) PE20020968A1 (es)
PL (1) PL205465B1 (es)
PT (2) PT2289539E (es)
RS (1) RS51579B (es)
RU (1) RU2311922C2 (es)
SI (1) SI1381385T1 (es)
TW (1) TWI301761B (es)
WO (1) WO2002076495A1 (es)
ZA (1) ZA200306637B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2198181C2 (ru) * 1997-03-20 2003-02-10 Ново Нордиск А/С Не содержащие цинк кристаллы инсулина для применения в легочных композициях
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20050250676A1 (en) * 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
DE10250297A1 (de) * 2002-10-29 2004-05-19 Aventis Pharma Deutschland Gmbh Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung
WO2004096266A1 (en) * 2003-05-02 2004-11-11 Novo Nordisk A/S Improved physical stability of insulin formulations
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
WO2005072803A1 (en) * 2004-01-16 2005-08-11 Biodel, Inc. Sublingual drug delivery device
ATE470433T1 (de) * 2004-02-13 2010-06-15 Nod Pharmaceuticals Inc Partikel mit kern aus calciumphosphat- nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung
PL1740154T3 (pl) * 2004-03-12 2009-11-30 Biodel Inc Kompozycje insuliny o ulepszonym wchłanianiu
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
JP2006087815A (ja) * 2004-09-27 2006-04-06 Canon Inc 噴霧方法および該方法に基づく噴霧装置
US20060194762A1 (en) * 2004-12-23 2006-08-31 Olaf Reer Composition comprising an epothilone and methods for producing a composition comprising an epothilone
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
PL1969004T3 (pl) * 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
AU2007238114B2 (en) 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
EP2152243A2 (en) * 2007-04-30 2010-02-17 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
WO2009065126A2 (en) * 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
AU2009203809B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
KR101239008B1 (ko) * 2008-03-31 2013-03-04 한양대학교 산학협력단 바일산 유도체 및 그의 응용
JP2010063762A (ja) * 2008-09-12 2010-03-25 Yoshiharu Masui 抗菌消臭剤
HUE068164T2 (hu) 2008-10-17 2024-12-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
WO2010049488A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
HUE027239T2 (en) * 2009-06-26 2016-10-28 Novo Nordisk As Preparation containing insulin, nicotinamide and arginine
WO2011003822A2 (de) * 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Insulinzubereitungen enthaltend methionin
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN104010652A (zh) 2011-10-27 2014-08-27 卡斯西部储备大学 超浓缩的速效胰岛素类似物制剂
WO2014076423A1 (fr) 2012-11-13 2014-05-22 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
ES2709339T3 (es) 2013-04-03 2019-04-16 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
TW201605489A (zh) * 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
EP3341403B1 (en) 2015-08-25 2022-01-05 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
JP2018531901A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CN105749292A (zh) * 2016-02-29 2016-07-13 苏州市贝克生物科技有限公司 促进胰岛素吸收的组合物及其制备方法
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
US20190282667A1 (en) 2016-09-29 2019-09-19 Arecor Limited Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
CN110662551B (zh) 2017-06-01 2023-07-18 伊莱利利公司 速效胰岛素组合物
CA3094237A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
JP7465813B2 (ja) 2018-04-04 2024-04-11 アレコル リミテッド インスリン化合物の送達のための医療用注入ポンプシステム
US20210113763A1 (en) 2018-04-04 2021-04-22 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤
CN115176155A (zh) 2019-10-25 2022-10-11 塞卡科实验室有限公司 指示剂化合物、包括指示剂化合物的装置及其制备和使用方法
MY208364A (en) 2019-12-11 2025-05-01 Novo Nordisk As Novel insulin analogues and uses thereof
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3758683A (en) 1971-04-30 1973-09-11 R Jackson Insulin product
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1527605A (en) 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3064888D1 (en) 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
JPS55153712A (en) 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
DE3033127A1 (de) 1980-09-03 1982-04-08 Hoechst Ag, 6000 Frankfurt Neue analoga des insulins
JPS58501125A (ja) 1981-07-17 1983-07-14 ノルデイスク・インスリンラボラトリウム 安定な水性治療性インシユリン製剤及びその製造方法
NL193099C (nl) 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
DE3316363A1 (de) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen Walzenrost fuer muellverbrennungsanlagen
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327713A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Wasserloesliche disazoverbindungen, verfahren zu deren herstellung und ihre verwendung als farbstoffe
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
CA1244347A (en) * 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations
EP0166971B1 (de) 1984-06-09 1990-02-28 Hoechst Aktiengesellschaft Insulinzubereitungen, Verfahren zu deren Herstellung und deren Verwendung
KR860001166B1 (ko) * 1984-06-15 1986-08-20 곽성일 신발 결착용 구멍쇠의 제조방법
DE3440988A1 (de) 1984-11-09 1986-07-10 Hoechst Ag, 6230 Frankfurt Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
IL78425A (en) * 1985-04-15 1991-05-12 Lilly Co Eli Intranasal formulation containing insulin
DE3526995A1 (de) 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3541856A1 (de) 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
US5496924A (en) 1985-11-27 1996-03-05 Hoechst Aktiengesellschaft Fusion protein comprising an interleukin-2 fragment ballast portion
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
DE3544295A1 (de) 1985-12-14 1987-06-19 Bayer Ag Thermoplastische formmassen mit hoher kriechstromfestigkeit
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
CA1339416C (en) 1987-02-25 1997-09-02 Liselotte Langkjaer Insulin derivatives
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
DE3726655A1 (de) 1987-08-11 1989-02-23 Hoechst Ag Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
US6875589B1 (en) 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
US5358857A (en) 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
US5397771A (en) 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5614219A (en) 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
EP0615445B1 (de) 1991-12-05 1996-05-15 ALFATEC-PHARMA GmbH Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
US6468959B1 (en) 1991-12-05 2002-10-22 Alfatec-Pharm Gmbh Peroral dosage form for peptide containing medicaments, in particular insulin
SG46612A1 (en) 1992-12-02 1998-02-20 Hoechst Ag Process for obtaining proinsulin in processing correctly linked cystine bridges
AU680462B2 (en) 1992-12-18 1997-07-31 Eli Lilly And Company Insulin analogs
DE4400709B4 (de) * 1993-01-13 2005-06-23 Denso Corp., Kariya Schraubenfestziehvorrichtung
US5606203A (en) * 1993-01-20 1997-02-25 Kabushiki Kaisha Toshiba Semiconductor device having Al-Cu wiring lines where Cu concentration is related to line width
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
DE4405179A1 (de) 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
BR9509201A (pt) 1994-09-09 1997-12-30 Takeda Chemical Industries Ltd Preparação de liberação sustemtada uso de um sal de metal polivalente insolúvel em água ou ligeiramente solúvel em água e processo para produzir uma preparação de liberação sustentada
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
WO1996041606A2 (en) 1995-06-08 1996-12-27 Therexsys Limited Improved pharmaceutical compositions for gene therapy
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
DE19707245A1 (de) * 1997-02-25 1998-08-27 Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh Verfahren zur Herstellung einer elektrischen Glühlampe
US6043214A (en) 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
RU2198181C2 (ru) * 1997-03-20 2003-02-10 Ново Нордиск А/С Не содержащие цинк кристаллы инсулина для применения в легочных композициях
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
AU1375199A (en) 1997-11-12 1999-05-31 Alza Corporation Method for decreasing self-association of polypeptides
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
PL197504B1 (pl) 1998-10-16 2008-04-30 Novo Nordisk As Trwałe stężone preparaty insulinowe do podawania do płuc
CA2346884A1 (en) 1998-10-16 2000-04-27 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
JP2002529514A (ja) 1998-11-18 2002-09-10 ノボ ノルディスク アクティーゼルスカブ フェノール及びクレゾールを要さない安定なインスリン水性調製物
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1187639A1 (en) * 1999-06-04 2002-03-20 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE60020382T2 (de) 1999-09-21 2006-01-26 Skyepharma Canada Inc., Verdun Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
AU2001264789A1 (en) 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
KR100508695B1 (ko) 2001-02-13 2005-08-17 한국과학기술연구원 인슐린의 경구투여용 제형과 그의 제조방법
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
US20040265268A1 (en) 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US20050123509A1 (en) 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
AU2002335046A1 (en) 2001-10-19 2003-05-06 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia

Also Published As

Publication number Publication date
EP1381385A1 (de) 2004-01-21
MXPA03007942A (es) 2004-04-02
RS51579B (sr) 2011-08-31
RU2311922C2 (ru) 2007-12-10
HRP20030765B1 (en) 2011-10-31
US7205277B2 (en) 2007-04-17
CA2441260C (en) 2011-04-26
KR20040011483A (ko) 2004-02-05
CA2441260A1 (en) 2002-10-03
DK1381385T3 (da) 2011-06-06
US20030004096A1 (en) 2003-01-02
SI1381385T1 (sl) 2011-05-31
EP2289539A1 (de) 2011-03-02
HU228847B1 (en) 2013-06-28
US7205276B2 (en) 2007-04-17
ES2393180T3 (es) 2012-12-19
CN1498113A (zh) 2004-05-19
HRP20030765A2 (en) 2005-06-30
CY1113318T1 (el) 2016-04-13
NO20034125L (no) 2003-11-11
CN1273187C (zh) 2006-09-06
NZ528335A (en) 2005-03-24
PE20020968A1 (es) 2002-12-10
KR20100061868A (ko) 2010-06-09
IL158057A (en) 2013-10-31
US20090186807A1 (en) 2009-07-23
US6960561B2 (en) 2005-11-01
IL158057A0 (en) 2004-03-28
AR096376A2 (es) 2015-12-23
US20050187142A1 (en) 2005-08-25
NO20034125D0 (no) 2003-09-16
US20070155653A1 (en) 2007-07-05
EP2289539B1 (de) 2012-09-19
ME00408B (me) 2011-10-10
US7452860B2 (en) 2008-11-18
NO326780B1 (no) 2009-02-16
CY1111413T1 (el) 2015-08-05
BR0208210A (pt) 2004-03-09
PT1381385E (pt) 2011-03-17
RU2003131187A (ru) 2005-03-10
BRPI0208210B8 (pt) 2021-05-25
HK1061521A1 (en) 2004-09-24
HUP0303596A2 (hu) 2004-01-28
DK2289539T3 (da) 2013-01-14
PT2289539E (pt) 2012-11-20
JP4231292B2 (ja) 2009-02-25
BRPI0208210B1 (pt) 2018-05-02
AU2002302409B2 (en) 2007-01-04
MEP60808A (en) 2011-05-10
MY129417A (en) 2007-03-30
TWI301761B (en) 2008-10-11
HUP0303596A3 (en) 2005-11-28
PL362800A1 (en) 2004-11-02
US7696162B2 (en) 2010-04-13
JP2004523589A (ja) 2004-08-05
WO2002076495A1 (de) 2002-10-03
EP1381385B1 (de) 2011-02-09
DE50214903D1 (de) 2011-03-24
YU73503A (sh) 2006-05-25
DE10114178A1 (de) 2002-10-10
US20050187143A1 (en) 2005-08-25
ATE497777T1 (de) 2011-02-15
KR100987311B1 (ko) 2010-10-13
PL205465B1 (pl) 2010-04-30
ES2360505T3 (es) 2011-06-06
ZA200306637B (en) 2004-05-07

Similar Documents

Publication Publication Date Title
AR033059A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada.
ECSP045496A (es) "preparaciones acidas de insulina con estabilidad mejorada"
CY1114631T1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
AR030245A1 (es) Composiciones de gel que contienen metronidazol
FI964285A0 (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
AR011611A1 (es) Composiciones en gel postespumante
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
DK1187601T3 (da) Hidtil ukendt præparat og administrationsform som omfatter en syrelabil protonpumpeinhibitor
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
ATE99943T1 (de) Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
AR022009A1 (es) Composiciones herbicidas
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
AR025573A1 (es) Composicion laxante
AR025243A1 (es) Composicion liquida de pesticida.
ATE367165T1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen
PE20040471A1 (es) Formulaciones de liberacion prolongada en forma de suspension
DE60232271D1 (de) Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen
GR1001067B (el) Νέες κτηνιατρικές και προστι?έμενες συν?έσεις προστασίας φυτών.
AR030647A1 (es) Composicion farmaceutica con actividad de agua especifica
ES2078727T3 (es) Composiciones farmaceuticas.
RU2001100069A (ru) Антгельминтное средство
EA200400954A1 (ru) Фармацевтическая композиция, содержащая 2,2-дихлор-12-(4-хлорфенил)додекановую кислоту
PE20241354A1 (es) Formulaciones conservadas

Legal Events

Date Code Title Description
FC Refusal